MedTrace Logo

Prognostic Value of PtcO2 in Patients With COVID-19

NCT05682612 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2023-10-12

No results posted yet for this study

Summary

Five percent of patients with COVID-19 progressed to respiratory failure and required ICU admission, such patients often have abnormal oxygen tolerance. However, there is still a lack of clinical indicators to predict the prognosis and treatment responsiveness of COVID-19.

Conditions

  • COVID-19 Acute Respiratory Distress Syndrome

Interventions

OTHER

outcome

hospital survivors and nonsurvivors

OTHER

Subtype of COVID-19

Different subtype of COVID-19

Sponsors & Collaborators

  • Southeast University, China

    lead OTHER

Principal Investigators

  • Jingyuan Xu, M.D. · Southeast University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-09
Primary Completion
2023-12-01
Completion
2023-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05682612 on ClinicalTrials.gov